JPS6230168B2 - - Google Patents
Info
- Publication number
- JPS6230168B2 JPS6230168B2 JP2110779A JP2110779A JPS6230168B2 JP S6230168 B2 JPS6230168 B2 JP S6230168B2 JP 2110779 A JP2110779 A JP 2110779A JP 2110779 A JP2110779 A JP 2110779A JP S6230168 B2 JPS6230168 B2 JP S6230168B2
- Authority
- JP
- Japan
- Prior art keywords
- indenyloxymethyl
- morpholine
- methanol
- amitriptyline
- acid addition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 150000003839 salts Chemical class 0.000 claims description 8
- 239000002253 acid Substances 0.000 claims description 6
- MADRVGBADLFHMO-GFCCVEGCSA-N (2r)-2-(3h-inden-4-yloxymethyl)morpholine Chemical compound C=1C=CC=2C=CCC=2C=1OC[C@H]1CNCCO1 MADRVGBADLFHMO-GFCCVEGCSA-N 0.000 claims description 4
- 239000004480 active ingredient Substances 0.000 claims description 3
- 230000002996 emotional effect Effects 0.000 claims 1
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 36
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 16
- 239000000935 antidepressant agent Substances 0.000 description 7
- 229940005513 antidepressants Drugs 0.000 description 7
- 229960000836 amitriptyline Drugs 0.000 description 6
- KRMDCWKBEZIMAB-UHFFFAOYSA-N amitriptyline Chemical compound C1CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 KRMDCWKBEZIMAB-UHFFFAOYSA-N 0.000 description 6
- 210000004556 brain Anatomy 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- KEBHLNDPKPIPLI-UTONKHPSSA-N (2r)-2-(3h-inden-4-yloxymethyl)morpholine;hydrochloride Chemical compound Cl.C=1C=CC=2C=CCC=2C=1OC[C@H]1CNCCO1 KEBHLNDPKPIPLI-UTONKHPSSA-N 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 230000001430 anti-depressive effect Effects 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- MADRVGBADLFHMO-UHFFFAOYSA-N Indeloxazine Chemical compound C=1C=CC=2C=CCC=2C=1OCC1CNCCO1 MADRVGBADLFHMO-UHFFFAOYSA-N 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 229940076279 serotonin Drugs 0.000 description 3
- HCYAFALTSJYZDH-UHFFFAOYSA-N Desimpramine Chemical compound C1CC2=CC=CC=C2N(CCCNC)C2=CC=CC=C21 HCYAFALTSJYZDH-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 229960003914 desipramine Drugs 0.000 description 2
- 230000008451 emotion Effects 0.000 description 2
- 210000001320 hippocampus Anatomy 0.000 description 2
- -1 lithium dibenzoyltartrate Chemical compound 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 210000003568 synaptosome Anatomy 0.000 description 2
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
- YONLFQNRGZXBBF-KBPBESRZSA-N (2s,3s)-2,3-dibenzoyloxybutanedioic acid Chemical compound O([C@H](C(=O)O)[C@H](OC(=O)C=1C=CC=CC=1)C(O)=O)C(=O)C1=CC=CC=C1 YONLFQNRGZXBBF-KBPBESRZSA-N 0.000 description 1
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- PHVGLTMQBUFIQQ-UHFFFAOYSA-N Nortryptiline Chemical compound C1CC2=CC=CC=C2C(=CCCNC)C2=CC=CC=C21 PHVGLTMQBUFIQQ-UHFFFAOYSA-N 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 229920001429 chelating resin Polymers 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000008717 functional decline Effects 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- KEBHLNDPKPIPLI-UHFFFAOYSA-N hydron;2-(3h-inden-4-yloxymethyl)morpholine;chloride Chemical compound Cl.C=1C=CC=2C=CCC=2C=1OCC1CNCCO1 KEBHLNDPKPIPLI-UHFFFAOYSA-N 0.000 description 1
- 229960004801 imipramine Drugs 0.000 description 1
- BCGWQEUPMDMJNV-UHFFFAOYSA-N imipramine Chemical compound C1CC2=CC=CC=C2N(CCCN(C)C)C2=CC=CC=C21 BCGWQEUPMDMJNV-UHFFFAOYSA-N 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- ZEABYRLMGDTEAI-UHFFFAOYSA-M lithium;methanol;hydroxide Chemical compound [Li+].[OH-].OC ZEABYRLMGDTEAI-UHFFFAOYSA-M 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 150000002688 maleic acid derivatives Chemical class 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- 239000012452 mother liquor Substances 0.000 description 1
- 230000001722 neurochemical effect Effects 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 229960002748 norepinephrine Drugs 0.000 description 1
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 1
- 229960001158 nortriptyline Drugs 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 230000013275 serotonin uptake Effects 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 231100000691 up-and-down procedure Toxicity 0.000 description 1
Landscapes
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2110779A JPS55113717A (en) | 1979-02-24 | 1979-02-24 | Antidepressive drug |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2110779A JPS55113717A (en) | 1979-02-24 | 1979-02-24 | Antidepressive drug |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS55113717A JPS55113717A (en) | 1980-09-02 |
| JPS6230168B2 true JPS6230168B2 (enrdf_load_html_response) | 1987-07-01 |
Family
ID=12045645
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2110779A Granted JPS55113717A (en) | 1979-02-24 | 1979-02-24 | Antidepressive drug |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS55113717A (enrdf_load_html_response) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69422021T2 (de) * | 1993-02-10 | 2000-07-13 | Yamanouchi Pharmaceutical Co., Ltd. | Morpholinderivate |
-
1979
- 1979-02-24 JP JP2110779A patent/JPS55113717A/ja active Granted
Also Published As
| Publication number | Publication date |
|---|---|
| JPS55113717A (en) | 1980-09-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TW419471B (en) | Morpholine derivatives useful as tachykinin receptor antagonists, preparation thereof and pharmaceutical composition containing same | |
| CN101784273B (zh) | (2s，3r)‑n‑(2‑((3‑吡啶基)甲基)‑1‑氮杂双环[2.2.2]辛‑3‑基)苯并呋喃‑2‑甲酰胺、其新的盐形式和用法 | |
| KR910000251B1 (ko) | 비시클로 치환된 페닐아세토니트릴 유도체 | |
| JPH037251A (ja) | （―）―ｎ―メチル―３―（２―メチルフェノキシ）―３―フェニルプロピルアミンの製造法 | |
| GB2293168A (en) | Polymorphic form of a tachykinin receptor antagonist | |
| JPH0686449B2 (ja) | 新規キヌクリジン類、該化合物を含有する医薬組成物、及びその製造方法 | |
| CH644348A5 (fr) | Amino-ethers oxydes, leur procede de preparation et medicament les contenant. | |
| KR20200051776A (ko) | 베타-히드록시 헤테로사이클릭 아민 및 과혈당증의 치료에서의 이의 용도 | |
| CN110234636B (zh) | 包含哌醋甲酯前药的组合物，其制造和使用方法 | |
| US7691849B2 (en) | Carboxamidine derivatives and their use in the treatment of vascular diseases | |
| JP2004534008A (ja) | 新規なアムロジピンカンファースルホン酸塩及びその製造方法 | |
| DK166018B (da) | N-oe2-(4-fluorphenyl)-1-methyl)-ethyl-n-methyl-n-propynylamin, isomere og salte deraf, deres fremstilling og farmaceutiske praeparater indeholdende dem | |
| IE49301B1 (en) | A phenylalkylaminoethylsalicylamide,its preparation and pharmaceutical compositions containing it | |
| CN102140079B (zh) | 新乌碱及其制备方法和以该化合物为活性成分的药物组合物及用途 | |
| JPH04247082A (ja) | 新スピロ〔４．５〕デカン化合物および医薬品組成物 | |
| JPS6033424B2 (ja) | フェニルエチルアミンの誘導体、その製造方法およびフェニルエチルアミンの誘導体を有効成分とする高血圧および心臓血管病の治療薬 | |
| EP0571685A1 (en) | Aryloxyheteroarylpropylamines, their preparation and use | |
| JPS6230168B2 (enrdf_load_html_response) | ||
| DE69811520T2 (de) | 5,11-DIHYDROBENZ[b,e][1,4]OXAZEPIN-DERIVATE UND DIESE ENTHALTENDE MEDIZINISCHE ZUBEREITUNGEN | |
| FI61182C (fi) | Foerfarande foer framstaellning av farmaceutiskt aktiva butylaminderivat | |
| TWI233356B (en) | Citric acid salt of a therapeutic compound and pharmaceutical compositions thereof | |
| RU2677268C1 (ru) | Частичный агонист допаминовых D2/D3 рецепторов - метиламид 4-{ 2-[4-(2,3-дихлорфенил)-пиперазин-1-ил]-этил} -пиперидин-1-карбоновой кислоты, способы его получения (варианты) и применения | |
| RU2004539C1 (ru) | Полистиролсульфонат 4-[3-[этил[-3-(пропилсульфинил)-пропил) амино)-2-оксипропокси]бензонитрила в виде смеси стереоизомеров или чистого стереоизомера, обладающий антиаритмическим действием | |
| JPH0375527B2 (enrdf_load_html_response) | ||
| FI61871C (fi) | Analogifoerfarande foer framstaellning av antidepressivt verkande trifluormetylsubstituerade aralkylestrar av alanin |